H.R. 2581 would establish a demonstration program in the Medicare Advantage program, modify the open enrollment period for that program, and change payment rates for prescription drugs that are administered through items of durable medical equipment.
CBO estimates that enacting H.R. 2581 would decrease direct spending relative to current law by $225 million over the 2016-2025 period. Pay-as-you-go procedures apply because the bill would affect direct spending. Enacting the bill would not affect revenues.
H.R. 2581 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.
